Articles by November, 2025

According to FutureWise analysis the market for Generic Oncology Drugs in 2025 is US$ 26.47 billion, and is expected to reach US$ 42.59 billion by 2033 at a CAGR of 6.13%. The growth of the  market is driven by the rising global cancer burden and the demand for affordable treatment options, along with the expiration of patents for major branded drugs. Supportive regulations, advancements in manufacturing, and the rise of biosimilar products are also encouraging market adoption. Additionally, the focus on healthcare cost optimization and access to essential therapies enhances the outlook for generic oncology drugs worldwide. Generic oncology drugs are essential in contemporary cancer treatment, providing clinically equivalent and more affordable alternatives to branded medications. These generics share the same active pharmaceutical ingredients, strength, dosage form, route of administration, and therapeutic effectiveness as their reference products, ensuring that they deliver ... Continue reading →

According to FutureWise analysis, the Gingival Retraction Cords Market in 2025 is US$0.23 billion, and is expected to reach US$0.36 billion by 2033 at a CAGR of 5.76%.  The Gingival Retraction Cords Market is poised for significant growth, driven by a surge in dental disorders and an increasing appetite for both restorative and cosmetic dental procedures worldwide. As emerging economies enhance their dental healthcare infrastructure and oral health awareness rises, demand for these essential products is gaining momentum. Innovation is at the heart of this market's expansion, with cutting-edge advancements in cord materials. The introduction of non-impregnated and chemically impregnated cords is significantly improving tissue management and hemostasis, leading to better clinical outcomes that dental professionals are eager to embrace.  The aging global population is significantly influencing this trend. Older adults typically require more complex dental ... Continue reading →

According to FutureWise analysis the market for generic oncology sterile injectables in 2025 is US$ 20.13 billion, and is expected to reach US$ 43.21 billion by 2033 at a CAGR of 10.02%. The market is expanding due to rising cancer prevalence, the need for quick and effective treatments, and the demand for affordable options. Expiring patents on branded products and a growing pipeline of biosimilars are set to increase availability. Additionally, improvements in sterile manufacturing and supportive regulatory frameworks are enhancing production efficiency and market access. Generic oncology sterile injectables are essential to modern cancer treatment, providing cost-effective alternatives to branded injectable therapies used in chemotherapy, immunotherapy, and supportive care. These formulations are administered directly into the bloodstream or tissues, allowing for rapid therapeutic action and precise dosing, which are crucial in oncology where accuracy and efficacy are key. These ... Continue reading →

According to FutureWise analysis, the glass syringe market in 2025 is US$12.10 billion and is expected to reach US$32.27 billion by 2033, at a CAGR of 13.05%.  The Glass Syringe Market is experiencing significant growth, primarily driven by increasing demand for prefilled syringes used for the administration of biologics and vaccines. Glass syringes offer superior chemical inertness and stability, making them a preferred choice among healthcare professionals.  The global rise in immunization initiatives, fueled by enhanced pandemic preparedness and the development of biosimilar drugs, is further propelling this market. Additionally, the pharmaceutical industry’s stringent regulatory standards for parenteral drug packaging, along with a preference for glass syringes that effectively prevent drug-container interactions, are solidifying their popularity in healthcare settings worldwide. Innovations in borosilicate glass formulations are also improving the ... Continue reading →

According to FutureWise analysis, the glaucoma surgery devices market in 2025 is US$1.64 billion, and is expected to reach US$9.52 billion by 2033 at a CAGR of 24.59%. The Glaucoma Surgery Devices Market is experiencing significant growth, largely due to the increasing global prevalence of glaucoma, which now affects over 80 million people worldwide. As a leading cause of irreversible blindness, glaucoma poses a considerable challenge, particularly for aging populations.  Excitingly, innovations in the field are transforming patient care. Breakthroughs in minimally invasive glaucoma surgery (MIGS) are introducing devices that promise quicker recovery times, fewer complications, and better outcomes compared to traditional procedures like trabeculectomy.  Additionally, as healthcare spending rises in developing regions and access to advanced ophthalmic care improves, more patients are able to benefit from timely surgical interventions. The popularity of micro-stent ... Continue reading →

According to FutureWise analysis, the Genomic Cancer Panel and Profiling Market in 2025 is US$ 8.36 billion, and is expected to reach US$ 16.72 billion by 2033 at a CAGR of 9.05%. Market growth is driven by the rising adoption of precision oncology and increasing cancer prevalence, creating a demand for personalized treatment strategies. Advances in next-generation sequencing (NGS) and the use of multi-gene panels for early diagnosis and therapy selection are enhancing clinical adoption. Furthermore, increased investment in cancer research and supportive reimbursement frameworks are expected to boost global market expansion. Genomic cancer panel and profiling technologies have significantly changed the field of oncology by providing a deeper understanding of cancer at the molecular level. These sophisticated diagnostic tools analyze a wide range of genetic alterations, which include mutations, gene fusions, copy number variations, and biomarkers, across various cancer-related genes ... Continue reading →

According to FutureWise analysis the market for genomics and proteomics reagents, research kits and analytical instruments in 2025 is US$ 87.16 billion, and is expected to reach US$ 213.21 billion by 2033 at a CAGR of 11.83%. The market is rapidly expanding due to increased investments in biomedical research, demand for precision medicine, and the adoption of advanced sequencing and proteomic technologies. Innovations like automation, AI analytics, and cloud platforms are improving efficiency and accelerating discovery. Growing applications in drug development, biomarker discovery, and personalized diagnostics are also expected to drive significant market growth. Genomics and proteomics are key pillars of modern molecular biology and biomedical research, providing essential tools for scientists to investigate the structure, function, and interactions of genes and proteins in unprecedented detail. These fields are critical for understanding biological mechanisms, diagnosing diseases, ... Continue reading →

According to FutureWise analysis, the glioblastoma multiforme treatment market in 2025 is US$2.81 billion, and is expected to reach US$6.03 billion by 2033 at a CAGR of 10.01%.  The Glioblastoma Multiforme Treatment Market is on the verge of significant breakthroughs during the forecast period, driven by an urgent need for effective treatments for this aggressive and deadly brain cancer. Currently, patients face a median survival rate of only 12-15 months after diagnosis. Exciting advancements are emerging, including innovative therapies such as CAR-T cell therapy, immune checkpoint inhibitors, targeted molecular treatments, and tumor-treating fields (TTFields) technology, all of which have shown promising results in clinical trials. The environment for progress is thriving, supported by increased research funding from both government agencies and private pharmaceutical companies. This influx of resources is catalyzing a wave of innovation. Additionally, the rise of ... Continue reading →

According to FutureWise analysis, the Genomics In Cancer Care Market in 2025 is US$ 19.04 billion, and is expected to reach US$ 47.95 billion by 2033 at a CAGR of 12.24%. This growth is fueled by the rise of precision oncology, increasing cancer incidence, and the use of next-generation sequencing for early diagnosis and personalized treatment. Advancements in liquid biopsy, companion diagnostics, and biomarker-driven therapies are boosting clinical integration. Additionally, growing investment in genomic research and supportive reimbursement policies are improving accessibility and expanding global market opportunities. Genomics has fundamentally transformed cancer care, allowing clinicians and researchers to explore cancer at the molecular and genetic levels. By analyzing DNA, RNA, and gene expression patterns found in tumors, genomics offers essential insights into the specific mutations and biological pathways involved in cancer development, progression, and treatment resistance. ... Continue reading →

According to FutureWise analysis, the glucose biosensors market in 2025 is US$11.54 billion and is expected to reach US$25.29 billion by 2033 at a CAGR of 10.3%.  The Glucose Biosensors Market is set for impressive growth over the coming years, driven by the increasing global prevalence of diabetes, which currently affects over 530 million adults worldwide. A significant factor contributing to this growth is the rising preference for continuous glucose monitoring (CGM) systems. These innovative solutions provide real-time data, making it more comfortable compared to traditional finger-prick testing.  Exciting technological advancements are also transforming glucose monitoring. Non-invasive and minimally invasive biosensors, including implantable devices with extended wear times, are making it easier for patients to manage their conditions. Additionally, smartphone-integrated monitoring systems and AI-powered predictive algorithms are enhancing glycemic control and improving ... Continue reading →